Sarah Konigsberg, MD
Endocrinology, Diabetes & Metabolism · Omaha, NENPI 1356460547
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 132 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 10.7% — the pattern of someone who eats at a lot of different presentations.
Across 132 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$262
- Novo Nordisk$242
- Bayer$199
- Abbott$194
- Amgen$176
- Nestle Healthcare Nutrition Inc.$150
- plus $1K from 24 others
Across 34 payments — averaging $7337.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dexcom, Inc.$129K
- AbbVie$107K
- Pfizer$13K
What the payments were for
- Food & beverage$2,452100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 17 | $262 |
| Novo Nordisk | 11 | $242 |
| Bayer | 11 | $199 |
| Abbott | 12 | $194 |
| Amgen(2 entities) | 11 | $176 |
| Nestle Healthcare Nutrition Inc. | 1 | $150 |
| Medtronic(2 entities) | 6 | $135 |
| Mannkind Corporation | 4 | $130 |
| Sanofi-aventis U.S. LLC | 5 | $94 |
| BETA Bionics, Inc. | 7 | $89 |
| AbbVie | 5 | $83 |
| Radius Health, Inc. | 5 | $83 |
| Ascensia Diabetes Care US Inc. | 4 | $79 |
| Antares Pharma, Inc. | 3 | $66 |
| Insulet Corporation | 4 | $66 |
| Tandem Diabetes Care, Inc. | 5 | $62 |
| Boehringer Ingelheim | 3 | $44 |
| Xeris Pharmaceuticals, Inc. | 2 | $34 |
| Dexcom, Inc. | 2 | $32 |
| Johnson & Johnson | 2 | $30 |
| Ascendis Pharma Endocrinology Inc | 2 | $30 |
| Averitas Pharma Inc. | 1 | $28 |
| AstraZeneca | 2 | $27 |
| Halozyme Inc | 1 | $22 |
| Soleno Therapeutics, Inc. | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Cequr Corporation | 1 | $17 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| Sequel Med Tech, LLC | 1 | $15 |
| Madrigal Pharmaceuticals | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZENPEP$150
How this compares
$2,452 in reported general payments places this provider in the 55th percentile of 43 endocrinology, diabetes & metabolism providers in Nebraska.
See all endocrinology, diabetes & metabolism providers in Nebraska →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 242 | $233,731 |
| MounjaroTirzepatide | 107 | $122,352 |
| JardianceEmpagliflozin | 90 | $72,497 |
| TrulicityDulaglutide | 51 | $71,342 |
| Tresiba Flextouch U-200Insulin Degludec | 56 | $70,019 |
| Tresiba Flextouch U-100Insulin Degludec | 127 | $64,489 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 40 | $63,171 |
| Humalog Kwikpen U-100Insulin Lispro | 172 | $43,432 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 45 | $40,359 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 68 | $33,263 |
| Humalog Kwikpen U-200Insulin Lispro | 17 | $31,502 |
| Novolog FlexpenInsulin Aspart | 135 | $31,372 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $22,800 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 177 | $21,645 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 15 | $21,467 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $242 | $272,881305 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $262 | $203,396200 claims |
| Boehringer IngelheimJardiance, Tradjenta | $44 | $81,820105 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $94 | $21,36224 claims |
| AstraZenecaFarxiga | $27 | $20,31726 claims |
| AbbVieSynthroid | $83 | $16,222189 claims |
| Johnson & JohnsonInvokana | $30 | $8,63311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 43 endocrinology, diabetes & metabolism providers in Nebraska.
Other endocrinology, diabetes & metabolism in Omaha
- Marium IlahiOmaha$170K
- Cyrus DesouzaOmaha$86K
- Timothy WahlOmaha$41K
- Leslie EilandOmaha$17K
- Anupam KotwalOmaha$17K
- John GallagherOmaha$15K
- Andjela DrincicOmaha$14K
- Laura Graeff-ArmasOmaha$11K
- Claire BakerOmaha$6K
- Alain TaylonOmaha$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.